Mark Jason Heath Ellison - Jun 27, 2022 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC. (OPNT)

Role
Chief Development Officer
Signature
/s/ Mark Jason Heath Ellison
Stock symbol
OPNT
Transactions as of
Jun 27, 2022
Transactions value $
$0
Form type
4
Date filed
6/29/2022, 04:07 PM
Previous filing
Jan 5, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPNT Common Stock Award $0 +2K +10.19% $0.00 21.6K Jun 27, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the acquisition of shares upon the determination on June 27, 2020 by the Compensation and Human Capital Committee of the Board of Directors of the Issuer that the performance conditions were met with respect to a portion of the performance stock units granted to the Reporting Person on January 4, 2022.